- Home
- DSL vs PRAX Comparison
DSL vs PRAX Comparison
Compare DSL & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- PRAX
- Stock Information
- Founded
- DSL 2013
- PRAX 2015
- Country
- DSL United States
- PRAX United States
- Employees
- DSL N/A
- PRAX N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- PRAX Health Care
- Exchange
- DSL Nasdaq
- PRAX Nasdaq
- Market Cap
- DSL 1.4B
- PRAX 1.5B
- IPO Year
- DSL N/A
- PRAX 2020
- Fundamental
- Price
- DSL $12.62
- PRAX $73.00
- Analyst Decision
- DSL
- PRAX Strong Buy
- Analyst Count
- DSL 0
- PRAX 9
- Target Price
- DSL N/A
- PRAX $146.33
- AVG Volume (30 Days)
- DSL 412.7K
- PRAX 315.5K
- Earning Date
- DSL 01-01-0001
- PRAX 11-06-2024
- Dividend Yield
- DSL 10.30%
- PRAX N/A
- EPS Growth
- DSL N/A
- PRAX N/A
- EPS
- DSL N/A
- PRAX N/A
- Revenue
- DSL N/A
- PRAX $1,605,000.00
- Revenue This Year
- DSL N/A
- PRAX N/A
- Revenue Next Year
- DSL N/A
- PRAX N/A
- P/E Ratio
- DSL N/A
- PRAX N/A
- Revenue Growth
- DSL N/A
- PRAX N/A
- 52 Week Low
- DSL $10.22
- PRAX $16.08
- 52 Week High
- DSL $12.96
- PRAX $86.93
- Technical
- Relative Strength Index (RSI)
- DSL 39.54
- PRAX 50.90
- Support Level
- DSL $12.59
- PRAX $70.03
- Resistance Level
- DSL $12.95
- PRAX $73.49
- Average True Range (ATR)
- DSL 0.08
- PRAX 4.10
- MACD
- DSL -0.02
- PRAX -0.17
- Stochastic Oscillator
- DSL 5.08
- PRAX 48.89
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.